BeiGene's Anti-PD-1 Approved in China for 4th and 5th Indications
publication date: Jun 23, 2021
BeiGene, a Beijing biotech, reported its anti-PD-1 antibody tislelizumab has been approved in China for two new indications, bringing the total to five. The new indications are first-line treatment for advanced non-squamous non-small cell lung cancer and conditional approval as a second-line therapy for hepatocellular carcinoma. In China, tislelizumab in now approved for lung, liver, bladder and lymphoma cancers. Earlier this year, BeiGene out-licensed global ex-China rights for tislelizumab to Novartis in a $2.2 billion agreement. More details....
Stock Symbols: (NSDQ: BGNE; HK: 06160) (NYSE: NVS)
Share this with colleagues:
To gain access to the members only content click here to subscribe.
You will be given immediate access to premium content on the site.